medRxiv PreprintsInternational16 November 2026
Updated outcome of patients with lung only osteosarcoma recurrence following surgical resection enrolled in phase 2 clinical trials: A report from the Children's Oncology Group
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
Objective: Osteosarcoma is a rare primary bone cancer of adolescents and young adults without significant improvement in treatments or outcomes in several decades. Resection is standard of care for recurrent disease. Patients with lung only osteosarcoma recurrence following surgical resection (LOOR-FSR) may present the most meaningful opportunity for impactful intervention but alternative trial endpoints to objective response are needed. Here we update benchmarks for LOOR-FSR with contemporary clinical trial data. Patients/Methods: This study included patients with pathologically confirmed LOO
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Unmet needs of Polish patients with cystic fibrosis seen through the lens of crowdfunding20 November 2026
- Motherly Plus: Study Protocol of a Randomized Controlled Trial Evaluating a Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression20 November 2026
- Targeting memory consolidation in major depression via pharmacological slow-wave sleep promotion20 November 2026
- Epidemiology of Cardiac Structure and Function Among African Caribbeans in Tobago: A Population-based Cohort Study20 November 2026
- Depressive Symptom Trajectories and Incident Cognitive Impairment by Outcome Ascertainment20 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.